The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease
Abstract
OBJECTIVE: To examine the influence of the APOE genotype on levels of beta-amyloid (Abeta) plaque load and atrophy in patients with Alzheimer disease (AD) in vivo. METHODS: Thirty-two patients with moderate AD were divided into carriers and noncarriers of the epsilon4 allele. These groups were matched for age, disease duration, education, and cognitive impairment. In all subjects, [11C]PIB-PET was performed for measurement of cerebral Abeta plaque deposition and cranial MRI for the assessment of gray matter volume by voxel-based morphometry (VBM) and for correction of partial volume effects (PVE) in the PET data. Voxel-based comparisons (SPM5) were performed between patient groups and healthy control populations and completed with multiple regression analyses between imaging data and epsilon4 allele frequency. RESULTS: Compared to controls, AD-typical patterns of [11C]PIB retention and atrophy were detected in both epsilon4-positive and epsilon4-negative patient groups. In direct comparison, significantly stronger and more extended [11C]PIB uptake was found in epsilon4-positive patients in bilateral temporoparietal and frontal cortex, surviving PVE correction. VBM analysis demonstrated comparable levels of atrophy in both patient groups. Regression analyses revealed a linear association between higher epsilon4 allele frequency and stronger temporoparietal Abeta plaque deposition, independently of other confounds. No major correlation between epsilon4 allele frequency and gray matter decrease was observed. CONCLUSION: These results indicate that the epsilon4-positive APOE genotype not only represents a risk factor for Alzheimer disease (AD), but also results in higher levels of Abeta plaque deposition in epsilon4-positive patients with AD compared to age-matched epsilon4-negative patients with similar levels of cognitive impairment and brain atrophy. The potential role of Abeta plaque imaging for patient inclusion and follow-up in anti-amyloid therapy trials is strengthened by these findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Plaque deposition is increased with APOE4 compared with APOE2 and APOE3 in humans and transgenic mice expressing familial AD (FAD) mutations (FAD-Tg) (2)(3)(4)(5).”
From APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease (2012) · cites this paper as [4]
In the citing paper
“The primary genetic risk factor for Alzheimer disease (AD) 4 is APOE4, increasing the risk by ϳ4and 15-fold with a single or double allele, whereas APOE2 reduces the risk compared with APOE3.”
From APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease (2012) · cites this paper as [4]
Citations
Cites
Thresholding of statistical maps in functional neuroimaging using the false discovery rate
Genovese, C. R., Lazar, N. A., & Nichols, T. (2002) · NeuroImage · doi:10.1006/nimg.2001.1037 · Cited by 4,923
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036
Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
In Vivo Mapping of Gray Matter Loss with Voxel-Based Morphometry in Mild Alzheimer's Disease
Baron, J., Chételat, G., Desgranges, B., Perchey, G., Landeau, B., Sayette, V. D. L., & Eustache, F. (2001) · NeuroImage · doi:10.1006/nimg.2001.0848 · Cited by 699
Berg, L., McKeel, D. W., Miller, J. P., Storandt, M., Rubin, E. H., Morris, J. C., Baty, J., Coats, M., Norton, J., Goate, A. M., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.326 · Cited by 657
Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein
Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Niinistö, L., Halonen, P., & Kontula, K. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331902 · Cited by 493
PET imaging of amyloid in Alzheimer's disease
Nordberg, A. K. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00853-1 · Cited by 462
Decreases in regional cerebral blood flow with normal aging
Martin, A. J., Friston, K. J., Colebatch, J. G., & Frackowiak, R. S. J. (1991) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1991.121 · Cited by 393
Flagged first, then by citations
Research works printed but not linked: 1
- Grundman M Black R. Clinical trials of bapineuzumab a beta-amyloid-targeted immunotherapy in patients with mild-to-moderate Alzheimer’s disease. In: International Conference on Alzheimer’s Disease (ICAD)
Cited by
Sorted by citations
Items 201–248 of 248
Yee, A., Tsui, N. B. Y., Kwan, R. Y. C., Leung, A. Y. M., Lai, C. K. Y., Chung, T., Lau, J. Y. N., Fok, M., Dai, D., & Lau, L. T. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210324111401 · Cited by 3
Mendel, T. A., & Gromadzka, G. (2010) · Neurologia i Neurochirurgia Polska · doi:10.1016/s0028-3843(14)60157-2 · Cited by 3
Shao, J., Yang, Q., Wohlschläger, A. M., & Sorg, C. (2012) · International Journal of Knowledge Discovery in Bioinformatics · doi:10.4018/jkdb.2012010102 · Cited by 3
Self-citationWang, D., Xu, C., Wang, W., Lu, H., Zhang, J., Liang, F., & Li, X. (2022) · Brain Sciences · doi:10.3390/brainsci12050515 · Cited by 3
Achouri-Rassas, A., Ali, N., Fray, S., Kechaou, M., Zakraoui, N. O., Fredj, S. H., Cherif, A., Anane, N., Echebi, S., Messaoud, T. B., et al. (2015) · Revue Neurologique · doi:10.1016/j.neurol.2015.10.001 · Cited by 2
Kang, D. W., Wang, S., Um, Y. H., Kim, N. Y., Lee, C. U., & Lim, H. K. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220427 · Cited by 2
Fall, A. B., Preti, M. G., Eshmawey, M., Kagerer, S. M., Ville, D. V. D., Unschuld, P. G., & (ADNI), A. D. N. I. (2024) · NeuroImage Clinical · doi:10.1016/j.nicl.2024.103635 · Cited by 2
PET Tracers for Beta-Amyloid and Other Proteinopathies
Nordberg, A. K. (2014) · Springer eBooks · doi:10.1007/978-3-642-42014-6_8 · Cited by 2
Amyloid imaging for Alzheimer's disease
Kerchner, G. A. (2011) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2011.617365 · Cited by 2
Li, W., Xie, Y., Yu, T., Wu, W., Wang, K., Wu, S., Zhao, Q., Zhang, X., Li, M., Liu, R., et al. (2020) · Chinese Journal of Academic Radiology · doi:10.1007/s42058-020-00043-1 · Cited by 2
Introduction to Alzheimer’s Disease
Manivasagam, T., Surya, R., Jayalakshmi, M., Thenmozhi, A. J., Prema, A., Qoronfleh, M. W., Alharbi, H. F., & Rajamani, Y. (2023) · Nutritional neurosciences · doi:10.1007/978-981-99-0677-2_1 · Cited by 2
PET Imaging Agents for Alzheimer’s Disease
Choi, S., Plöessl, K., Zhu, L., & Kung, H. F. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_18 · Cited by 2
Diagnosis of Dementia Using Nuclear Medicine Imaging Modalities
Merissa, N., Garrett, M., & Scott, P. J. H. (2011) · InTech eBooks · doi:10.5772/25283 · Cited by 2
Möglichkeiten moderner Bildgebungstechnologien im Rahmen der Frühdiagnostik von Alzheimererkrankung
Unschuld, P. G. (2015) · Therapeutische Umschau · doi:10.1024/0040-5930/a000674 · Cited by 1
A Complex Case of Major Neurocognitive Disorder: Alzheimer’s Disease
Krishna, P. M., Shivakumar, K., & Amanullah, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-70311-4_1 · Cited by 1
Copolymer-1 as a potential therapy for mild cognitive impairment
Abraham, D. I., Salazar, F. E., & Ibarra, A. (2022) · Brain and Cognition · doi:10.1016/j.bandc.2022.105892 · Cited by 1
Structural Differences Between Apolipoprotein E3 and E4 as Measured by 19F- NMR
Garai, K., Mutafi, S. M., Baban, B. A., & Frieden, C. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2009.12.3577 · Cited by 2
Virta, J. J. (2012) · UTUPub (University of Turku)
Genetic Risk Factors of Imaging Measures Associated with Late-Onset Alzheimer’s Disease
Reitz, C. (2012) · InTech eBooks · doi:10.5772/22794
Applications of Neuroimaging in Behavioral Medicine
Gray, M. A., Gianaros, P. J., & Critchley, H. (2010) · Springer eBooks · doi:10.1007/978-0-387-09488-5_51
Drzezga, A. E., & Perneczky, R. (2010) · The Open Nuclear Medicine Journal · doi:10.2174/1876388x01002010053
Self-citationCapacités de réserve, vieillissement cérébral et maladie d'Alzheimer
Foubert-Samier, P. A. (2013) · theses.fr (ABES)
Klinischer Nutzen nuklearmedizinischer Verfahren in der Demenzdiagnostik
Drzezga, A. E. (2009) · Nervenheilkunde · doi:10.1055/s-0038-1627142
Self-citationMagnetic resonance studies in Alzheimer´s disease
Westman, E. (2009) · Figshare
Shi, Z., Ying, W., Liu, S., Liu, S., Zhou, Y., Wang, J., Gao, S., & Ji, Y. (2014) · DOAJ (DOAJ: Directory of Open Access Journals)
Rodriguez, G. A. (2014) · DigitalGeorgetown (Georgetown University Library)
Miettinen, T. (2015) · Tampere University Institutional Repository (Tampere University)
O4‐01‐02: Meta‐analytic comparison of PiB‐PET and FDG‐PET results in Alzheimer's disease and MCI
He, W., Xu, J., Shi, J.-Q., & Radua, J. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.1635
Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E
Liao, F., & Holtzman, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00010-1
Tsolaki, A. (2015) · Advances in psychology, mental health, and behavioral studies (APMHBS) book series · doi:10.4018/978-1-4666-8234-4.ch002
Biomarkers of Alzheimer’s Disease
Saeed, U., Swardfager, W., Black, S. E., & Masellis, M. (2017) · Mental health and illness worldwide · doi:10.1007/978-981-10-0370-7_8-1
Biomarkers in dementia with Lewy bodies
Donaghy, P. C. (2016)
Imaging of Brain Amyloid Load in Early Alzheimer’s Disease
Grimmer, T., & Perryman, J. G. (2018) · Neuromethods · doi:10.1007/978-1-4939-7674-4_9
Self-citationSaeed, U. (2018) · TSpace (University of Toronto)
A study of the global effects of Apolipoprotein E using lipidomics
Hawksworth, J. I. (2019) · ORCA Online Research @Cardiff (Cardiff University)
APOE as a Risk Factor for Age‐Related Cognitive Impairment
Korthauer, L. E., & Driscoll, I. F. (2020) · The Wiley Encyclopedia of Health Psychology · doi:10.1002/9781119057840.ch35
Grimmer, T., Drzezga, A. E., & Kurz, A. (2010) · Der Nervenarzt
Self-citationCurrent awareness in geriatric psychiatry
John Wiley & Sons, L. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2121
Kotze, M. J., & Stein, D. J. (2010) · doi:10.1002/9780470669600.ch51
Nordberg, A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-397025-1.00071-3
Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment
Doering, E., Hoenig, M. C., Bischof, G. N., Bohn, K. P., Ellingsen, L. M., van Eimeren, T., Drzezga, A. E., & Initiative, A. D. N. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05879-6
Self-citationThe Effect of Aβ Regulating ApoE ɛ4 on Cognitive Function in MCI
王, 希. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1482311
Baek, M. S., Cho, H., Lee, H. S., Lee, J. H., Ryu, Y. H., & Lyoo, C. H. (2020) · Figshare · doi:10.6084/m9.figshare.13174043
Brugulat‐Serrat, A., Sánchez-Benavides, G., Cacciaglia, R., Salvadó, G., Shekari, M., Collij, L. E., Buckley, C. J., van Berckel, B. N. M., Perissinotti, A., Niñerola-Baizán, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26572156
Li, L., Yu, X., Sheng, C., Jiang, X., Zhang, Q., Han, Y., & Jiang, J. (2022) · Figshare · doi:10.6084/m9.figshare.21130048
Wang, X., Zhang, C., Liu, X., Tai, Y., Ma, G., Kong, M., Ba, M., & Initiative, A. D. N. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261435429
AD-FTLD Spectrum: New Understanding of the Neurodegenerative Process from the Study of Risk Genes
Takeda, M., Kudo, T., Tanaka, T., Okochi, M., Hashimoto, R., Morihara, T., & Tagami, S. (2010) · Springer eBooks · doi:10.1007/978-4-431-53871-4_17
Metadata
- Authors
- Drzezga, A., Grimmer, T., Henriksen, G., Mühlau, M., Perneczky, R., Miederer, I., Praus, C., Sorg, C., Wohlschläger, A., Riemenschneider, M., Wester, H. J., Foerstl, H., Schwaiger, M., & Kurz, A.
- Affiliations
- Technical University of Munich (DE)
- From the Departments of Nuclear Medicine (A.D., G.H., I.M., C.P., A.W., H.J.W., M.S.), Psychiatry and Psychotherapy (T.G., R.P., C.S., M.R., H.F., A.K.), Neurology (M.M.), and Neuroradiology (A.W.), Technische Universität München, Munich, Germany.
- ORCID
- Venue
- Neurology
- Published
- 2009-04-28
- Volume
- 72
- Issue
- 17
- Pages
- 1487-1494
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2050255138
- Cited by
- 248
- References
- 38
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 7 · 2023: 4 · 2022: 16 · 2021: 6 · 2020: 8 · 2019: 9 · 2018: 17 · 2017: 13 · 2016: 16 · 2015: 18 · 2014: 22 · 2013: 15 · 2012: 25
- FWCI
- 18.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- APOE ε4, Alzheimer's disease, amyloid plaques, gray matter atrophy, 11C-PiB PET, amyloid imaging, genetic risk factors, temporoparietal cortex, partial volume correction
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Apolipoproteins E, Brain, Carbon Radioisotopes, DNA Mutational Analysis, Female, Gene Frequency, Genetic Testing, Genotype, Humans, Male, Middle Aged, Polymorphism, Genetic, Risk Factors, Thiazoles, Amyloid beta-Peptides, Genetic Predisposition to Disease, Positron-Emission Tomography, Benzothiazoles, Apolipoprotein E4, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
